Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd has announced that its Board of Directors will convene on July 27, 2026. The primary agenda items include the consideration and approval of the unaudited consolidated and standalone financial results for the quarter ended June 30, 2026. The company also noted that the trading window for dealing in its securities, which was closed from July 1, 2026, will remain shut until 48 hours after the financial results are approved and submitted to the stock exchanges. This aligns with the company's Insider Trading Code.

Senores Pharmaceuticals Limited has submitted its Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2026, as per Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018. The report, issued by Company Secretary Tapan Shah, confirms the company's capital structure, equity share position across NSDL, CDSL, and physical forms, and details demat activities. The issued equity share capital stands at 4,60,53,588 shares. The report indicates 65.03% held in dematerialized form in NSDL and 34.97% in CDSL, totaling 100% dematerialized shares. No differences were noted between issued and listed capital, and no changes in share capital were reported during the quarter.

Senores Pharmaceuticals Limited announced an outcome of its Board Meeting held on June 29, 2026. The Board, on the recommendation of the Audit Committee, has approved a variation in the utilization of unutilized IPO proceeds. The company plans to reallocate ₹1000.16 million from the total IPO proceeds of ₹5000.00 million. This proposed variation is subject to the approval of the shareholders through a postal ballot. The board meeting commenced at 04:15 P.M. (IST) and concluded at 05:00 P.M. (IST). The company will also host this information on its website.

Senores Pharmaceuticals Limited has announced the closure of its trading window for directors, promoters, designated persons, and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from July 01, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. This measure is to prevent potential insider trading activities during the period leading up to and immediately following the financial results announcement. The exact date of the board meeting to approve these results will be communicated separately.

Senores Pharmaceuticals Limited has updated its disclosure authorization following the resignation of its Company Secretary and Compliance Officer, Mr. Vinay Kumar Mishra, effective June 10, 2026. The company has authorized its Managing Director, Mr. Swapnil Jatinbhai Shah, and Whole Time Director & CFO, Mr. Deval Rajnikant Shah, to determine the materiality of events and make disclosures to the stock exchanges as per SEBI (LODR) Regulations, 2015. This update follows their earlier intimation on May 14, 2026, regarding Mr. Mishra's resignation.

Senores Pharmaceuticals Ltd. reported no deviations or variations in the utilization of funds raised through the preferential issue of 11,70,000 convertible equity warrants for the quarter ended March 31, 2026. The funds, amounting to ₹95,00,40,000, were raised on March 28, 2026. The Audit Committee reviewed the statement, and the Board of Directors took it on record on May 14, 2026. The original allocation included funding working capital (₹31,25,30,000), product development (₹25,00,00,000), subsidiary investment (₹15,00,00,000), and general corporate purposes (₹23,75,10,000).

Senores Pharmaceuticals Ltd. reported a correction to its previously released media statement regarding the audited financial results for the quarter and fiscal year ending March 31, 2026. The corrected release highlights strong financial performance, with total income for FY26 reaching ₹664 Cr, a 62% increase year-over-year. EBITDA grew by 96% to ₹200 Cr, and PAT increased by 108% to ₹122 Cr. The company also noted significant growth in regulated markets, emerging markets, and branded generics businesses, along with strategic acquisitions and joint ventures to expand its market presence.

Senores Pharmaceuticals Ltd reported no deviation or variation in the utilization of funds raised through its IPO for the quarter ended March 31, 2026. The IPO raised ₹500 Crores. While some delays occurred in deploying funds for the Havix subsidiary due to geopolitical issues, the company received management approval to utilize the funds by Fiscal 2027. The audit committee and board of directors reviewed and approved the statement on May 14, 2026.

Senores Pharmaceuticals Ltd. has released the Monitoring Agency Report for the quarter ended March 31, 2026, as per SEBI regulations. The report, issued by CARE Ratings Limited, concerns the utilization of IPO proceeds. The Audit Committee and Board of Directors reviewed and recorded the report on May 14, 2026. The report indicates a delay in implementing one of the objects which was scheduled to get completed by FY26.

Senores Pharmaceuticals Ltd announced its audited consolidated and standalone financial results for FY26. The company reported a 65% increase in total income to ₹664 Cr and a 114% increase in EBITDA to ₹200 Cr. PAT increased by 108% to ₹122 Cr. The company highlighted strong growth in regulated markets, emerging markets, and branded generics businesses, along with strategic acquisitions and a joint venture in the U.S. Federal Market.